NEW! UCB to Acquire Candid Therapeutics

UCB to Acquire Neurona Therapeutics

UCB FY25 Documents

Title Format Download
Integrated Annual Report FY25 - EN
PDF
Integrated Annual Report FY25 - EN
xbri
Integrated Annual Report FY25 - FR
PDF
Integrated Annual Report FY25 - FR
xbri
Integrated Annual Report FY25 - NL
PDF
Integrated Annual Report FY25 - NL
xbri
Facts & Figures FY25
PDF
Excel File
xlsx

JP Morgan Documents

Other documents

Title Format Download
Aide-Mémoire FY25
PDF
Capital Market Call 29.09.2025 - Galvokimig
PDF
Capital Market Call 22.09.2025 - BIMZELX® (bimekizumab) in Hidradenitis Suppurativa
PDF

Discover the life of an HS patient; Watch the The Unbearable Home video here

EMTN Program

Debt Financing
EMTN Prospectus Archive
Go to EMTN program

Scientific Presentations, Abstracts, 
Posters, and Publications for Shareholders, Investors, and other Capital Market Participants Only

The following documents are specifically for shareholders, investors, and other capital market participants. The webpages are not intended for members of the general public.

Corporate Governance Documents



Also find more information on the dedicated section of our website.

 

 

 

UCB Reports Archive

Title Year Format Download
Half-Year Report 2025 PDF
Integrated Annual Report 2024 PDF
Integrated Annual Report 2024 ESEF
Half-Year Report 2024 PDF
Integrated Annual Report 2023 PDF

Investor Relations Team

Please reach us via investor-relations@ucb.com or a specific team member:

Yvonne Naughton

Head of Investor Relations

+44-175-344 7521

Yvonne.Naughton@ucb.com

Sahar Yazdian

Investor Relations Lead Lead

+32 2 559 9137
Sahar.Yazdian@ucb.com

Diyana Mishu

Investor Relations Manager

+32 2 559 7446

Diyana.Mishu@ucb.com

Yifei (Faye) Wu

Assistant Assistant Assistant  

+32 2 559 9087

Yifei.Wu@ucb.com